Lessons to Improve Quality in Oncology Practice: Road Map to Fill the Global Gaps

Abstract

Oncology is a medical branch devoted to the study, diagnosis, treatment, and prevention of cancer. Cancer prevalence is increasing. By 2030, the global cancer burden is expected to grow to 21.7 million new cases and 13 million deaths. Developing as well as developed nations have cancer burden, but there is a gap. Ideally, cancer management involves a multidisciplinary team composed of qualified individuals from different specialties collaborating to optimize the care. This team must follow evidence-based medicine principles, considering three questions: What is the problem? How can we manage it? And why are we selecting this pathway? To fill the gaps in care, we present 10 questions that can help those who are managing patients with cancer globally. We concluded that although there is no “one-size-fits-all” approach, adhering to basic principles can help guide provision of evidence-based patient-centered care and fill some of the gaps in oncology.

Cancer Burden Among Arab World Males in 2020: The Need for a Better Approach to Improve Outcome

“… 21 On the basis of all the above, more attention toward improving the cancer care services is required. 24 …”

“…21 On the basis of all the above, more attention toward improving the cancer care services is required. 24 The strengths of this work come from the recent estimates of the cancer statistics, the multinational Arab collaboration, and input from different countries and across the world, being the first collective review concerning AMCs as a spectrum, compared with Arab females' cancers and worldwide males. Also, it can be a cornerstone for the following in-depth studies and analyses.…”

Cancer Burden Among Arab-World Females in 2020: Working Toward Improving Outcomes

“…Furthermore, a relative improvement in the most aggressive cancers' MIR was observed between 2018 and 2020, including liver (0.99-0.96), lung (0.92-0.89), stomach (0.87-0.82), and leukemia (0.83-0.72), excluding the esophagus (0.95-0.96), which increased, and the pancreas, which remained stable (0.95). This modest improvement, especially for liver cancer, which previously had the most unfavorable MIR, might reflect the advances in cancer screening, comprehensive multidisciplinary and evidence-based management guidelines, 22 including improved surgical approaches, precision radiotherapy techniques (such as stereotactic ablative and image-guided radiosurgery and radiotherapy), 23 and adoption of new targeted and immunotherapeutic options.…”